ArticleCost effectiveness and resource allocation : C/E2026
Pragmatic health technology appraisals of biosimilars: a pilot case study of bevacizumab in colorectal cancer for NICE.
Matthew D Stevenson et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.